NCT06472895View on ClinicalTrials.gov

A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 20, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2027

Conditions
Renal Cell Carcinoma
Interventions
DRUG

AK112 monotherapy

A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER

NCT06472895 - A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter